Advances in Bladder Cancer Imaging

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2013 Apr 12

PMID 23574966

Citations 24

Authors

Shaista Hafeez

Robert Huddart

Affiliations

Soon will be listed here.

Abstract

The purpose of this article is to review the imaging techniques that have changed and are anticipated to change bladder cancer evaluation. The use of multidetector 64-slice computed tomography (CT) and magnetic resonance imaging (MRI) remain standard staging modalities. The development of functional imaging such as dynamic contrast-enhanced MRI, diffusion-weighted MRI and positron emission tomography (PET)-CT allows characterization of tumor physiology and potential genotypic activity, to help stratify and inform future patient management. They open up the possibility of tumor mapping and individualized treatment solutions, permitting early identification of response and allowing timely change in treatment. Further validation of these methods is required however, and at present they are used in conjunction with, rather than as an alternative to, conventional imaging techniques.

Citing Articles

Assessment of pathological grade and variants of bladder cancer with a continuous-time random-walk diffusion model.

Wang W, Wu J, Shen Q, Li W, Xue K, Yang Y Front Oncol. 2024; 14:1431536.

PMID: 39211555 PMC: 11357921. DOI: 10.3389/fonc.2024.1431536.

Magnetic resonance radiographic features which might lead to misdiagnosis of muscle-invasive bladder cancer based on vesical imaging reporting and data system: the application experience of a single center.

Li B, Li X, Li Z, Yang P, Pan C, Tian L Quant Imaging Med Surg. 2023; 13(10):7258-7268.

PMID: 37869292 PMC: 10585496. DOI: 10.21037/qims-23-356.

Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy.

Hafeez S, Koh M, Jones K, Ghzal A, dArcy J, Kumar P Front Oncol. 2022; 12:961393.

PMID: 36452501 PMC: 9702046. DOI: 10.3389/fonc.2022.961393.

The role of radiomics with machine learning in the prediction of muscle-invasive bladder cancer: A mini review.

Huang X, Wang X, Lan X, Deng J, Lei Y, Lin F Front Oncol. 2022; 12:990176.

PMID: 36059618 PMC: 9428259. DOI: 10.3389/fonc.2022.990176.

Mapping Local Failure Following Bladder Radiotherapy According to Dose.

Abdel-Aty H, Warren-Oseni K, Bagherzadeh-Akbari S, Hansen V, Jones K, Harris V Clin Oncol (R Coll Radiol). 2022; 34(10):e421-e429.

PMID: 35691760 PMC: 9515812. DOI: 10.1016/j.clon.2022.05.003.

References

Ahlstrom H, Malmstrom P, Letocha H, Andersson J, Langstrom B, Nilsson S . Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol. 1996; 37(2):180-5. DOI: 10.1177/02841851960371P137. View

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

Rioja J, Rodriguez-Fraile M, Lima-Favaretto R, Rincon-Mayans A, Penuelas-Sanchez I, Zudaire-Bergera J . Role of positron emission tomography in urological oncology. BJU Int. 2010; 106(11):1578-93. DOI: 10.1111/j.1464-410X.2010.09510.x. View

Tritschler S, Mosler C, Tilki D, Buchner A, Stief C, Graser A . Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. Urology. 2012; 79(6):1317-21. DOI: 10.1016/j.urology.2012.01.040. View

Vesselle H, MIRALDI F . FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics. 1998; 18(4):805-23; discussion 823-4. DOI: 10.1148/radiographics.18.4.9672967. View

Kundra V, Silverman P . Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol. 2003; 180(4):1045-54. DOI: 10.2214/ajr.180.4.1801045. View

Kruger S, Buck A, Mottaghy F, Hasenkamp E, Pauls S, Schumann C . Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009; 36(11):1807-12. DOI: 10.1007/s00259-009-1181-2. View

Liu I, Lai Y, Espiritu J, Segall G, Srinivas S, Nino-Murcia M . Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int. 2006; 77(1):69-75. DOI: 10.1159/000092937. View

de Jong I, Pruim J, Elsinga P, Jongen M, Mensink H, Vaalburg W . Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging. 2002; 29(10):1283-8. DOI: 10.1007/s00259-002-0881-7. View

10.

Abu-Yousef M, NARAYANA A, Brown R, Franken Jr E . Urinary bladder tumors studied by cystosonography. Part II: Staging. Radiology. 1984; 153(1):227-31. DOI: 10.1148/radiology.153.1.6473786. View

11.

Ah-See M, Makris A, Taylor N, Harrison M, Richman P, Burcombe R . Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2008; 14(20):6580-9. DOI: 10.1158/1078-0432.CCR-07-4310. View

12.

Lu Y, Chen J, Liang J, Wang H, Lin C, Lin W . Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2011; 81(9):2411-6. DOI: 10.1016/j.ejrad.2011.07.018. View

13.

Harisinghani M, Saini S, Hahn P, Weissleder R, Mueller P . MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (Combidex). Acad Radiol. 1998; 5 Suppl 1:S167-9, discussion S183-4. DOI: 10.1016/s1076-6332(98)80095-0. View

14.

Harry V, Semple S, Gilbert F, Parkin D . Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol. 2008; 111(2):213-20. DOI: 10.1016/j.ygyno.2008.07.048. View

15.

Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T . Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009; 251(1):112-21. DOI: 10.1148/radiol.2511080873. View

16.

Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K . Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007; 67(6):2773-82. DOI: 10.1158/0008-5472.CAN-06-1630. View

17.

Kosuda S, Kison P, Greenough R, Grossman H, Wahl R . Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med. 1997; 24(6):615-20. DOI: 10.1007/BF00841398. View

18.

Bernhardt T, Schmidl H, Philipp C, Allhoff E, Rapp-Bernhardt U . Diagnostic potential of virtual cystoscopy of the bladder: MRI vs CT. Preliminary report. Eur Radiol. 2003; 13(2):305-12. DOI: 10.1007/s00330-002-1444-9. View

19.

Saksena M, Dahl D, Harisinghani M . New imaging modalities in bladder cancer. World J Urol. 2006; 24(5):473-80. DOI: 10.1007/s00345-006-0118-7. View

20.

Kramer-Marek G, Kiesewetter D, Martiniova L, Jagoda E, Lee S, Capala J . [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging. 2007; 35(5):1008-18. PMC: 2365742. DOI: 10.1007/s00259-007-0658-0. View